A company profile of Amgen Inc., a biotechnology company that specializes in molecular and cellular biology, is presented. An overview of the company is given, along with key facts including contact information, products portfolio, number of employees and revenues. A SWOT analysis is provided ...
Onyx Pharmaceuticals had been acquired by Amgen and as part their restructuring strategy, a number of employees were laid off including myself. Onyx was a wonderful, meaningful place to work--great culture, very caring of their employees, supportive. I worked with a dedicated and hard working ...
AMGEN SPECIFICALLY DISCLAIMS ANY LIABILITY, WHETHER BASED IN CONTRACT, TORT, STRICT LIABILITY OR OTHERWISE, FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL OR SPECIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH ACCESS TO OR USE OF THE SERVICES, EVEN IF AMGEN HAS BEEN ADVISED OF THE POSSIBIL...
An overview of the company is given, along with key facts including head office address, contact information, web site address, revenue and turnover, as well as the number of employees. A SWOT analysis is provided which includes strengths, weaknesses, opportunities for improvement and threats. ...
Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsab...
The day will be hectic when we receive more number of volumes on to our Workflow. I learnt a lot here, since it is my first job. Like how to communicate with the clients, and how to solve problems when issue is raised by them etc. Management was good I had a great experience wo...
which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia...
Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.3% of net...
These companies may use information (not including your name, address email, address, or telephone number) obtained from cookies and web beacons about your visits to this site and other websites in order to measure advertising effectiveness and to provide advertisements about goods and services of ...
three or four more are coming very soon. So we feel we are testing in a range of indications. The biologically plausible and clinically relevant combinations will have data next year on a number of these. And to your point, the goal always in combination therapy beyond monotherapy is to enh...